Drug intelligence / Profile preview

STP2130

Development stage: Preclinical
Lead developer: ST Pharm
Modality: Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

STP2130 is a preclinical-stage mRNA-based vaccine candidate developed by ST Pharm for the prevention of COVID-19. The vaccine utilizes ST Pharm's proprietary mRNA platform, which includes their 'SmartCap' technology for efficient mRNA capping and lipid nanoparticle (LNP) delivery systems. STP2130 is designed to encode the SARS-CoV-2 spike protein, triggering the host's immune system to produce protective antibodies and cellular immune responses. As of 2024, the program remains in the preclinical phase of development as part of ST Pharm's broader mRNA vaccine portfolio.

Targets

Delta S (SARS-CoV-2 Delta spike protein)

Beyond the preview

Go deeper on STP2130.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STP2130.